Evidence map›Paper›PMID 32252490›Full record

ArticleInternational journal of molecular sciences2020

Impact of Type 2 Diabetes Mellitus on Human Bone Marrow Stromal Cell Number and Phenotypic Characteristics.

Féaron C Cassidy, Ciara Shortiss, Colin G Murphy, Stephen R Kearns, William Curtin, Ciara De Buitléir, Timothy O'Brien, Cynthia M Coleman

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Féaron C CassidyCollege of Medicine, Nursing and Health Science, School of Medicine, Regenerative Medicine Institute (REMEDI), National University of Ireland Galway (NUI Galway), H91 FD82 Galway, Ireland.
Ciara ShortissCollege of Medicine, Nursing and Health Science, School of Medicine, Regenerative Medicine Institute (REMEDI), National University of Ireland Galway (NUI Galway), H91 FD82 Galway, Ireland.ORCID 0000-0002-2936-3310
Colin G MurphyDepartment of Trauma and Orthopaedics, Galway University Hospitals, H91 YR71 Galway, Ireland.
Stephen R KearnsDepartment of Trauma and Orthopaedics, Galway University Hospitals, H91 YR71 Galway, Ireland.
William CurtinDepartment of Trauma and Orthopaedics, Galway University Hospitals, H91 YR71 Galway, Ireland.
Ciara De BuitléirSaolta University Healthcare Group, Galway University Hospital, H91 YR71 Galway, Ireland.
Timothy O'BrienCollege of Medicine, Nursing and Health Science, School of Medicine, Regenerative Medicine Institute (REMEDI), National University of Ireland Galway (NUI Galway), H91 FD82 Galway, Ireland.
Cynthia M ColemanCollege of Medicine, Nursing and Health Science, School of Medicine, Regenerative Medicine Institute (REMEDI), National University of Ireland Galway (NUI Galway), H91 FD82 Galway, Ireland.
Ollscoil na Gaillimhe – University of Galway · IEUniversity Hospital Galway · IESaolta University Health Care Group · IE

Funding

Diabetes Ireland HRB-MRCG-2016-2Health Research Board HRB-MRCG-2016-2
6 · The paper itself

Abstract

Human bone marrow-derived mesenchymal stromal cells (MSCs) have been investigated in numerous disease settings involving impaired regeneration because of the crucial role they play in tissue maintenance and repair. Considering the number of comorbidities associated with type 2 diabetes mellitus (T2DM), the hypothesis that MSCs mediate these comorbidities via a reduction in their native maintenance and repair activities is an intriguing line of inquiry. Here, it is demonstrated that the number of bone marrow-derived MSCs in people with T2DM was reduced compared to that of age-matched control (AMC) donors and that this was due to a specific decrease in the number of MSCs with osteogenic capacity. There were no differences in MSC cell surface phenotype or in MSC expansion, differentiation, or angiogenic or migratory capacity from donors living with T2DM as compared to AMCs. These findings elucidate the basic biology of MSCs and their potential as mediators of diabetic comorbidities, especially osteopathies, and provide insight into donor choice for MSC-based clinical trials. This study suggests that any role of bone marrow MSCs as a mediator of T2DM comorbidity is likely due to a reduction in the osteoprogenitor population size and not due to a permanent alteration to the MSCs' capacity to maintain tissue homeostasis through expansion and differentiation.

Indexed as

Bone Marrow CellsCell CountPhenotypeAdipogenesisAgedAged, 80 and overBiomarkersCell DifferentiationDiabetes Mellitus, Type 2HumansImmunophenotypingMesenchymal Stem CellsMiddle AgedOsteogenesisBiomarkersadult stem cellsbone marrow stromal cellsmesenchymal stem cellsmesenchymal stromal cellstype 2 diabetes mellitus

Identifiers

PMID32252490
PMCPMC7177361
OpenAlexW3014738766

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.